Pharmacologic Management of Obesity Clinical Practice Guidelines (AGA, 2022)

Clinical guidelines on the pharmacologic management of adults with obesity were published in October 2022 by the American Gastroenterological Association, in Gastroenterology.^[1]^[2]

It is recommended that when adults with obesity or overweight with weight-related complications have not responded adequately to lifestyle interventions, pharmacologic agents be added to these interventions.

It is suggested that semaglutide 2.4 mg with lifestyle modifications, rather than lifestyle modifications alone, be used to treat adults with obesity or overweight with weight-related complications.

It is suggested that liraglutide 3.0 mg with lifestyle modifications, rather than lifestyle modifications alone, be used to treat adults with obesity or overweight with weight-related complications.

It is suggested that phentermine-topiramate extended release (ER) with lifestyle modifications, rather than lifestyle modifications alone, be used to treat adults with obesity or overweight with weight-related complications.

It is suggested that naltrexone-bupropion ER with lifestyle modifications, rather than lifestyle modifications alone, be used to treat adults with obesity or overweight with weight-related complications.

It is suggested that orlistat not be used in adults with obesity or overweight with weight-related complications. Comment: Patients may reasonably choose orlistat therapy if the value they place on the potential small weight loss benefit is high and that they place on adverse gastrointestinal (GI) effects is low.

It is suggested that phentermine with lifestyle modifications, rather than lifestyle modifications alone, be used to treat adults with obesity or overweight with weight-related complications.

It is suggested that diethylpropion with lifestyle modifications, rather than lifestyle modifications alone, be used to treat adults with obesity or overweight with weight-related complications.

It is recommended that in adults whose body mass index (BMI) is between 25 and 40 kg/m², Gelesis100 oral superabsorbent hydrogel be used only in the context of a clinical trial.

For more information, please go to Obesity.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Pharmacologic Management of Obesity Clinical Practice Guidelines (AGA, 2022) - Medscape - Nov 02, 2022.

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

My Alerts